DGAP-Adhoc

SYGNIS AG receives commitment for the purchase of up to 2.7 million shares within the scope of a capital increase to finance the acquistion of Expedeon Holdings Ltd.

SYGNIS AG / Key word(s): Capital Increase

29.06.2016 19:00

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement according to § 15 WpHG

---------------------------------------------------------------------------
NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE USA, CANADA,
JAPAN AND AUSTRALIA


SYGNIS AG receives commitment for the purchase of up to 2.7 million shares
within the scope of a capital increase to finance the acquistion of
Expedeon Holdings Ltd.


Madrid, Spain and Heidelberg, Germany, 29 June 2016 - SYGNIS AG (Frankfurt:
LIO1; ISIN: DE000A1RFM03; Prime Standard) today received a binding
commitment for the purchase of up to 2.7 million new shares as part of the
previously announced cash capital increase to finance the acquisition of
Expedeon Holdings Ltd. Under the terms of the agreement signed today, the
investor has committed to purchase up to 2.7 million shares which are not
subscribed by SYGNIS or Expedeon shareholders in a private placement at a
price of EUR 1.10 per new share.

XXX end of ad hoc announcement XXX

For further information, please contact:


SYGNIS AG MC Services AG
Pilar de la Huerta Raimund Gabriel
CEO/CFO Managing Partner
Phone: [phone] Phone: [phone]
Email: [e-mail] Email: [e-mail]



About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes in the development
and commercialization of innovative products for DNA amplification and
sequencing. Based on its proprietary technologies, SYGNIS has developed a
commercial product portfolio addressing key challenges in the fast-growing
fields of molecular biology and next-generation sequencing applications.
Key products include the TruePrime(TM) product line and SensiPhi(R),
licensed to a leading industry partner, for whole genome DNA amplification
and sequencing, as well as the SunScript(TM) Reverse Transcriptase product
family to convert genetic information from RNA molecules back to DNA.
SYGNIS AG is listed on the German Stock Exchange in the Prime Standard
segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information
contained herein does not constitute an offer to sell or a solicitation of
an offer to purchase any securities of SYGNIS AG in the Federal Republic of
Germany nor under any other jurisdiction, in particular not where such kind